William J. Chase

CIK: 0001563572

Transaction Breakdown

Open Market Buys (P)1 (6.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)14 (93.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

GRAL

GRAIL, Inc.

Director

NTLA

Intellia Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (15 total)

GRAL
GRAIL, Inc.
Oct 15, 2026
Award(A)
Direct
153 shares at avg. $135.46$21K
GRAL
GRAIL, Inc.
Jul 15, 2026
Award(A)
Direct
276 shares at avg. $74.36$21K
GRAL
GRAIL, Inc.
Jun 18, 2026
Award(A)
Direct
5.5K shares at avg. $63.74$350K
NTLA
Intellia Therapeutics, Inc.
Jun 9, 2026
Award(A)
Direct
9.2K shares-
GRAL
GRAIL, Inc.
Apr 15, 2026
Award(A)
Direct
408 shares at avg. $49.79$20K
GRAL
GRAIL, Inc.
Jan 15, 2026
Award(A)
Direct
213 shares at avg. $97.44$21K
GRAL
GRAIL, Inc.
Oct 15, 2025
Award(A)
Direct
275 shares at avg. $75.52$21K
NTLA
Intellia Therapeutics, Inc.
Aug 20, 2025
Purchase(P)
Direct
100K shares at avg. $10.03$1.0M
GRAL
GRAIL, Inc.
Jul 15, 2025
Award(A)
Direct
533 shares at avg. $38.53$21K
NTLA
Intellia Therapeutics, Inc.
Jun 11, 2025
Award(A)
Direct
8K shares-
GRAL
GRAIL, Inc.
May 29, 2025
Award(A)
Direct
6.1K shares at avg. $41.10$250K
GRAL
GRAIL, Inc.
Apr 15, 2025
Award(A)
Direct
784 shares at avg. $25.94$20K
GRAL
GRAIL, Inc.
Jan 15, 2025
Award(A)
Direct
1.2K shares at avg. $17.58$21K
GRAL
GRAIL, Inc.
Oct 30, 2024
Award(A)
Direct
210 shares at avg. $13.62$3K
GRAL
GRAIL, Inc.
Oct 15, 2024
Award(A)
Direct
1.1K shares at avg. $14.01$15K

		Type	Shares	Price		Ownership
Oct 15, 2026	GRAL GRAIL, Inc.	Award(A)	153	$135.46	$20,725	Direct
Jul 15, 2026	GRAL GRAIL, Inc.	Award(A)	276	$74.36	$20,523	Direct
Jun 18, 2026	GRAL GRAIL, Inc.	Award(A)	5,491	$63.74	$349,996	Direct
Jun 9, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	9,200	-	$0	Direct
Apr 15, 2026	GRAL GRAIL, Inc.	Award(A)	408	$49.79	$20,314	Direct
Jan 15, 2026	GRAL GRAIL, Inc.	Award(A)	213	$97.44	$20,755	Direct
Oct 15, 2025	GRAL GRAIL, Inc.	Award(A)	275	$75.52	$20,768	Direct
Aug 20, 2025	NTLA Intellia Therapeutics, Inc.	Purchase(P)	100,000	$10.03	$1,003,000	Direct
Jul 15, 2025	GRAL GRAIL, Inc.	Award(A)	533	$38.53	$20,536	Direct
Jun 11, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	8,000	-	-	Direct
May 29, 2025	GRAL GRAIL, Inc.	Award(A)	6,082	$41.10	$249,970	Direct
Apr 15, 2025	GRAL GRAIL, Inc.	Award(A)	784	$25.94	$20,337	Direct
Jan 15, 2025	GRAL GRAIL, Inc.	Award(A)	1,182	$17.58	$20,780	Direct
Oct 30, 2024	GRAL GRAIL, Inc.	Award(A)	210	$13.62	$2,860	Direct
Oct 15, 2024	GRAL GRAIL, Inc.	Award(A)	1,054	$14.01	$14,767	Direct

1-15 of 15 transactions

About CHASE WILLIAM J

CHASE WILLIAM J (SEC CIK 0001563572) files insider reports with the SEC as Director of GRAIL, Inc. (GRAL) and Director of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 15 ownership filings by CHASE WILLIAM J, all Form 4s, filed between Oct 17, 2024 and Oct 16, 2026. Those filings report 15 transactions, from Oct 15, 2024 to Oct 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on CHASE WILLIAM J's filings is in SUNNYVALE, CA.

Recent filings by CHASE WILLIAM J

Oct 15, 2026: Grant or award of GRAL shares (Form 4, code A).
Jul 15, 2026: Grant or award of GRAL shares (Form 4, code A).
Jun 18, 2026: Grant or award of GRAL shares (Form 4, code A).
Jun 9, 2026: Grant or award of NTLA shares (Form 4, code A).
Apr 15, 2026: Grant or award of GRAL shares (Form 4, code A).

Other insiders filing for GRAIL, Inc. (GRAL)

SUMME GREGORY L, Director
Ofman Joshua J., Chief Executive Officer
MIZELL STEVEN, Director
Partridge Andrew John, Chief Growth Officer
Freidin Aaron, Chief Financial Officer
Krevans Sarah, Director

How to read Form 4 transaction codes